These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 16895957)

  • 1. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
    Sabolch A; Else T; Griffith KA; Ben-Josef E; Williams A; Miller BS; Worden F; Hammer GD; Jolly S
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):252-9. PubMed ID: 25754631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
    Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.
    Habra MA; Ejaz S; Feng L; Das P; Deniz F; Grubbs EG; Phan A; Waguespack SG; Ayala-Ramirez M; Jimenez C; Perrier ND; Lee JE; Vassilopoulou-Sellin R
    J Clin Endocrinol Metab; 2013 Jan; 98(1):192-7. PubMed ID: 23150683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy in adrenocortical carcinoma.
    Polat B; Fassnacht M; Pfreundner L; Guckenberger M; Bratengeier K; Johanssen S; Kenn W; Hahner S; Allolio B; Flentje M
    Cancer; 2009 Jul; 115(13):2816-23. PubMed ID: 19402169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
    Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
    Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
    Guelho D; Paiva I; Vieira A; Carrilho F
    Endocrinol Nutr; 2016 May; 63(5):212-9. PubMed ID: 26969077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
    Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
    Fassnacht M; Allolio B
    Clin Endocrinol (Oxf); 2010 Nov; 73(5):561-5. PubMed ID: 20738315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
    World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to radiation therapy in adrenocortical carcinoma.
    Hermsen IG; Groenen YE; Dercksen MW; Theuws J; Haak HR
    J Endocrinol Invest; 2010 Nov; 33(10):712-4. PubMed ID: 20220294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.